deltatrials
Recruiting PHASE2 Interventional 1-arm NCT04789109

CapTem Plus Radioembolization for NET Liver Metastases (CapTemY90)

UPCC04219 Phase 2 Study of Capecitabine-Temozolomide (CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2 Neuroendocrine Tumors

Sponsor: Abramson Cancer Center of the University of Pennsylvania

Conditions Liver Metastases Neuroendocrine Tumor Grade 2
Interventions Capecitabine tablets + temozolomide tablets + SIR-Spheres
Updated 2 times since 2021 Last updated: Oct 1, 2021 Started: Nov 30, 2021 Primary completion: Dec 31, 2024 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04789109, this PHASE2 trial focuses on Liver Metastases and Neuroendocrine Tumor Grade 2 and remains actively recruiting participants. Sponsored by Abramson Cancer Center of the University of Pennsylvania, it has been updated 2 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Apr 2021 – ~Nov 2021 · 7 months · monthly snapshotNot Yet Recruiting~Nov 2021 – present · 56 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Nov 2021 — Present [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Apr 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abramson Cancer Center of the University of Pennsylvania
  • CARTI
  • Roswell Park Cancer Institute
Data source: Abramson Cancer Center of the University of Pennsylvania

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations